-

CorVista Health to Present New Data on Non-Invasive Point of Care Test for Ischemia with Non-Obstructive Coronary Arteries Using Machine Learning at ACC.26

BETHESDA, Md.--(BUSINESS WIRE)--CorVista Health today announced the upcoming poster presentation of new data on its non-invasive point of care test for ischemia with non-obstructive coronary arteries (INOCA) – a common condition, particularly in women, where patients experience cardiovascular symptoms despite having no flow-limiting blockages in their major epicardial arteries – using machine learning at the American College of Cardiology’s Annual Scientific Session (ACC.26), taking place March 28-30, 2026, in New Orleans, LA.

Details of the presentations are as follows:

Title: Noninvasive Ischemia Detection in Symptomatic Patients: A Physiologic Feature Machine-Learned Model

Presenters:

  • Charles Bridges, EVP and Chief Scientific Officer, CorVista Health
  • Tim Burton, Data Scientist, CorVista Health

Format: Oral Poster

Presentation Number: Poster #78

Date and Time: Monday, March 30, 2026, at 12:30 p.m. ET – 1:30 p.m. ET

Location: Section 1590 (Ischemic Heart Diseases)

CorVista Health will be exhibiting in the Future Hub Booth #FH8, where attendees can learn about the CorVista System.

About CorVista System®

The CorVista System is an FDA-cleared, non-invasive cardiovascular diagnostics platform designed to analyze cardiac and hemodynamic signals using machine-learned algorithms. The system synchronously collects physiological signals during a brief point-of-care test and applies advanced analytics to identify patterns associated with pulmonary hypertension (PH) and coronary artery disease (CAD). The CorVista System delivers actionable diagnostic insights without the use of radiation, contrast agents, injections, fasting, or exercise. The CorVista System is developed and manufactured by Analytics For Life, Inc. and licensed to CorVista Health, Inc.

About CorVista Health

CorVista Health is dedicated to transforming cardiovascular care through innovative diagnostics that shorten the path from symptoms to diagnosis. By enabling earlier detection of complex cardiovascular conditions, CorVista aims to empower clinicians with actionable insights and improve patient outcomes across diverse care settings.

For more information on CorVista Health, please visit: www.corvista.com

Contacts

Media Contact: media@corvista.com

Industry:

CorVista Health

Release Versions
English

Contacts

Media Contact: media@corvista.com

More News From CorVista Health

CorVista Health Announces New AMA Category III CPT® Code for Augmentative AI Analysis of Cardiopulmonary Disease

BETHESDA, Md.--(BUSINESS WIRE)--CorVista Health, has announced that the American Medical Association (AMA) has granted a new Category III Current Procedural Terminology (CPT®) code for novel augmentative AI algorithmic analysis of potential coronary artery disease (CAD), pulmonary hypertension (PH), and elevated pulmonary capillary wedge pressure (PCWP). The new code encompasses the FDA-cleared CorVista® System for CAD and PH, as well as the anticipated PCWP Add-On algorithm which is currently...

CorVista Health Appoints Nikki Troiano Gainey as Chief Customer Officer and Names Ian Shadforth Chief Strategy Officer

BETHESDA, Md.--(BUSINESS WIRE)--CorVista Health today announced the appointment of Nikki Troiano Gainey as Chief Customer Officer. In this role, Gainey will lead CorVista's customer strategy, commercial execution, and market development, as the company expands adoption of the CorVista System, a non-invasive, point-of-care platform designed to support cardiovascular disease detection and clinical decision-making. As part of the leadership transition, Ian Shadforth has been appointed to the role...

CorVista Health Announces Collaboration with Mayo Clinic to Advance Next-Gen Pulmonary Hypertension Diagnosis

BETHESDA, Md.--(BUSINESS WIRE)--CorVista Health has announced a research collaboration with Mayo Clinic to evaluate how next-generation, non-invasive diagnostics may transform the identification and management of pulmonary hypertension (PH) – a complex and frequently underdiagnosed cardiovascular condition that affects an estimated one percent of the global population. Pulmonary hypertension is a progressive and potentially life-threatening condition characterized by elevated pressure in the pu...
Back to Newsroom